Anti-human CTGF antibody

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9587015
APP PUB NO 20140343258A1
SERIAL NO

14367081

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel anti-human CTGF antibodies having excellent binding activity and/or neutralizing activity, as compared with conventional anti-human CTGF antibodies, are useful for treating various diseases in which human CTGF is involved in pathogenesis, including renal diseases such as chronic kidney disease and diabetic nephropathy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Iwasaki, Shoji Tokyo, JP 10 103
Moriya, Ryuichi Tokyo, JP 11 38
Takakura, Koji Tokyo, JP 1 0
Yoshino, Masayasu Tokyo, JP 5 22

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 7, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 7, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00